5 Potential Catalysts Pin (Nasdaq: MDCX) To My Watchlist's Top Spot (Low Float Idea)

*Disseminated on behalf of Medicus Pharma Ltd.

July 6th

Greetings, Friend!

In the fast-paced life sciences sector, a few companies are gaining notice for developing innovative therapies targeting major unmet medical needs.

One little-known company's subsidiary is advancing a dissolvable microneedle patch to deliver chemotherapy directly to skin tumors, aiming to change treatment for basal cell carcinoma as we know it.

This non-invasive approach is in clinical trials in the U.S. and UAE and could offer a less invasive, more patient-friendly alternative to surgery or systemic drugs.

The company is also expanding through acquisitions, including a late-stage UK biotech focused on advanced prostate therapies, signaling a broader ambition in areas with high unmet needs.

Factor in a low float (under 3Mn shares), two analyst targets indicating significant upside potential, and a major acquisition proceeding forward, this Nasdaq profile could soon be attracting serious attention.

Consider Medicus Pharma Ltd. (Nasdaq: MDCX) for your radar.

Medicus Pharma Ltd. is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. The company is actively engaged in multiple countries, spread over three continents.

Complete Company Details - Medicus Pharma Ltd. (Nasdaq: MDCX)

Focus: Accelerating clinical development of novel therapeutics across multiple countries and continents.

Specialty: Moving innovative therapies quickly through clinical stages.

About SkinJect (Medicus Pharma's Wholly Owned Subsidiary)

Product: Patented dissolvable microneedle patch (D-MNA) for non-melanoma skin cancer, especially basal cell carcinoma.

Mechanism: Delivers doxorubicin directly to tumor via transdermal microneedles, aiming to replace invasive Mohs surgery with a painless, office-based treatment.

Rights: Exclusive global development and commercialization rights from University of Pittsburgh and Carnegie Mellon since 2016.

Clinical Progress

Phase 1 (2021): Demonstrated safety, tolerability, and some complete responses.

Phase 2: IND submitted to FDA in January 2024; patient recruitment began August 2024 at 9 US sites.

Interim analysis (March 2025): Over 60% complete clinical response; trial expanded from 60 to 90 patients.

SkinJect Value Proposition

Innovation: Patented, non-invasive microneedle patch for direct drug delivery to skin tumors.

Market: BCC is the most common cancer globally; North American market projected at $15Bn by 2030.

Clinical Results: Positive safety and efficacy data in early trials, with ongoing Phase 2 showing promise.

Leadership: Experienced management and board with oncology and drug development expertise.

Medicus Pharma (Nasdaq: MDCX) is positioned to impact standards of care in both human and veterinary medicine, with ongoing clinical and regulatory milestones.

Find Sources Here: MDCX Presentation. MDCX Website.

-----

5 Potential Catalysts Could Provide (Nasdaq: MDCX) With A Breakout Spark!

#1. A Low Float Scenario: With roughly 2.34Mn shares in its float, volatility potential could be heightened at the drop of a hat.

#2. Two Analyst Targets Suggest MDCX May Be Undervalued.

Take a look at these two targets found over at MarketBeat:

From Thursday's close, these targets project a potential upside of over 675% and 475%, respectively.

#3. Medicus Pharma Announces Definitive Agreement To Acquire Antev Ltd.

Medicus Pharma has entered a definitive agreement to acquire UK-based Antev Ltd.

This acquisition will expand Medicus’s pipeline into late-stage urology therapeutics, opening access to a $6Bn market and diversifying its portfolio, which could accelerate growth and strengthen its position in the biotech sector.

#4. Andrew Smith Appointed As Medicus Pharma Chief Operating Officer.

Medicus Pharma has appointed Andrew Smith as Chief Operating Officer (COO).

Bringing in experienced leadership can enhance operational efficiency and execution of strategic initiatives, supporting Medicus’s ongoing growth and clinical development plans.

Strong management is crucial for scaling operations and delivering on the company’s ambitious biotech pipeline.

#5. Medicus Pharma Submits Phase 2 Trial Protocol To FDA.

Medicus Pharma has announced the submission of its Phase 2 clinical trial protocol for its dissolvable microneedle patch targeting basal cell carcinoma to the FDA.

This milestone advances its lead asset toward regulatory approval, potentially validating its innovative technology and opening the door to a significant market opp. in skin cancer treatment.

-----

Now taking my watchlist's top spot: Medicus Pharma Ltd. (Nasdaq: MDCX).

Consider this biotech idea for your radar and keep your eyes peeled for updates.

All the best,

Dane James

Editor Market Pulse Today

(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)

*MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors.

Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 07/06/2025 and ending on 07/11/2025 to publicly disseminate information about (MDCX:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid seven thousand five hundred USD ("Funds"). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.

Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (MDCX:US).

Please see important disclosure information here: https://marketpulsetoday.com/disclosure/mdcx-ozsfc/#details

5 Potential Catalysts Pin (Nasdaq: MDCX) To My Watchlist's Top Spot (Low Float Idea)

0 Response to "5 Potential Catalysts Pin (Nasdaq: MDCX) To My Watchlist's Top Spot (Low Float Idea)"

Post a Comment